Oyster Point Pharma


# Oyster Point Pharma



40°40′43″N 78°14′35″W﻿ / ﻿40.678631°N 78.243038°W﻿ / 40.678631; -78.243038

**Oyster Point Pharma, Inc.** is an American biopharmaceutical company based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.


## Products

The lead product of the company is Tyrvaya. In October 2021, it was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.


## Initial public offering and stock history

Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018. In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.

In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31. In January 2023 Viatris acquired Oyster Point Pharma in an all-cash deal.

